Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Dual-targeting triplebody 33-16-123 (SPM-2) mediates effective redirected lysis of primary blasts from patients with a broad range of AML subtypes in combination with natural killer cells.

Braciak TA, Roskopf CC, Wildenhain S, Fenn NC, Schiller CB, Schubert IA, Jacob U, Honegger A, Krupka C, Subklewe M, Spiekermann K, Hopfner KP, Fey GH, Aigner M, Krause S, Mackensen A, Oduncu FS.

Oncoimmunology. 2018 Jul 30;7(9):e1472195. doi: 10.1080/2162402X.2018.1472195. eCollection 2018.

2.

The homeobox transcription factor HB9 induces senescence and blocks differentiation in hematopoietic stem and progenitor cells.

Ingenhag D, Reister S, Auer F, Bhatia S, Wildenhain S, Picard D, Remke M, Hoell JI, Kloetgen A, Sohn D, Jänicke RU, Koegler G, Borkhardt A, Hauer J.

Haematologica. 2019 Jan;104(1):35-46. doi: 10.3324/haematol.2018.189407. Epub 2018 Aug 9.

3.

CD19-specific triplebody SPM-1 engages NK and γδ T cells for rapid and efficient lysis of malignant B-lymphoid cells.

Schiller CB, Braciak TA, Fenn NC, Seidel UJ, Roskopf CC, Wildenhain S, Honegger A, Schubert IA, Schele A, Lämmermann K, Fey GH, Jacob U, Lang P, Hopfner KP, Oduncu FS.

Oncotarget. 2016 Dec 13;7(50):83392-83408. doi: 10.18632/oncotarget.13110.

4.

Image-Processing Scheme to Detect Superficial Fungal Infections of the Skin.

Mäder U, Quiskamp N, Wildenhain S, Schmidts T, Mayser P, Runkel F, Fiebich M.

Comput Math Methods Med. 2015;2015:851014. doi: 10.1155/2015/851014. Epub 2015 Nov 16.

5.

NK cells from an AML patient have recovered in remission and reached comparable cytolytic activity to that of a healthy monozygotic twin mediated by the single-chain triplebody SPM-2.

Braciak TA, Wildenhain S, Roskopf CC, Schubert IA, Fey GH, Jacob U, Hopfner KP, Oduncu FS.

J Transl Med. 2013 Nov 16;11:289. doi: 10.1186/1479-5876-11-289.

6.

Homeobox protein HB9 binds to the prostaglandin E receptor 2 promoter and inhibits intracellular cAMP mobilization in leukemic cells.

Wildenhain S, Ingenhag D, Ruckert C, Degistirici Ö, Dugas M, Meisel R, Hauer J, Borkhardt A.

J Biol Chem. 2012 Nov 23;287(48):40703-12. doi: 10.1074/jbc.M111.308965. Epub 2012 Oct 8.

7.

Expression of cell-cell interacting genes distinguishes HLXB9/TEL from MLL-positive childhood acute myeloid leukemia.

Wildenhain S, Ruckert C, Röttgers S, Harbott J, Ludwig WD, Schuster FR, Beldjord K, Binder V, Slany R, Hauer J, Borkhardt A.

Leukemia. 2010 Sep;24(9):1657-60. doi: 10.1038/leu.2010.146. Epub 2010 Jul 1. No abstract available.

PMID:
20596032
8.

Postoperative evaluation for disseminated medulloblastoma involving the spine: contrast-enhanced MR findings, CSF cytologic analysis, timing of disease occurrence, and patient outcomes.

Meyers SP, Wildenhain SL, Chang JK, Bourekas EC, Beattie PF, Korones DN, Davis D, Pollack IF, Zimmerman RA.

AJNR Am J Neuroradiol. 2000 Oct;21(9):1757-65.

9.

Acute stroke intervention with intraarterial urokinase infusion.

Barr JD, Mathis JM, Wildenhain SL, Wechsler L, Jungreis CA, Horton JA.

J Vasc Interv Radiol. 1994 Sep-Oct;5(5):705-13.

PMID:
8000119
10.

Postoperative evaluation for intracranial recurrence of medulloblastoma: MR findings with gadopentetate dimeglumine.

Meyers SP, Wildenhain S, Chess MA, Tarr RW.

AJNR Am J Neuroradiol. 1994 Sep;15(8):1425-34.

PMID:
7985559
11.

CT after intracranial intraarterial thrombolysis for acute stroke.

Wildenhain SL, Jungreis CA, Barr J, Mathis J, Wechsler L, Horton JA.

AJNR Am J Neuroradiol. 1994 Mar;15(3):487-92.

PMID:
8197945

Supplemental Content

Loading ...
Support Center